nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Dacarbazine—melanoma	0.0847	0.237	CbGbCtD
Bortezomib—CYP1A2—Carmustine—melanoma	0.0624	0.175	CbGbCtD
Bortezomib—CYP1A2—Vemurafenib—melanoma	0.0494	0.138	CbGbCtD
Bortezomib—CYP3A4—Temozolomide—melanoma	0.0472	0.132	CbGbCtD
Bortezomib—CYP2D6—Vemurafenib—melanoma	0.0407	0.114	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—melanoma	0.0378	0.106	CbGbCtD
Bortezomib—CYP3A4—Vemurafenib—melanoma	0.0259	0.0725	CbGbCtD
Bortezomib—CYP3A4—Docetaxel—melanoma	0.00887	0.0249	CbGbCtD
Bortezomib—PSMD1—hair follicle—melanoma	0.00622	0.0592	CbGeAlD
Bortezomib—PSMB2—skin epidermis—melanoma	0.00578	0.055	CbGeAlD
Bortezomib—PSMD2—hair follicle—melanoma	0.00551	0.0525	CbGeAlD
Bortezomib—PSMB5—hair follicle—melanoma	0.00484	0.0461	CbGeAlD
Bortezomib—PSMB1—hair follicle—melanoma	0.00423	0.0403	CbGeAlD
Bortezomib—PSMB2—hair follicle—melanoma	0.00412	0.0393	CbGeAlD
Bortezomib—SLC31A1—hair follicle—melanoma	0.00357	0.034	CbGeAlD
Bortezomib—CTSG—skin of body—melanoma	0.00335	0.0319	CbGeAlD
Bortezomib—PSMA1—skin of body—melanoma	0.00322	0.0306	CbGeAlD
Bortezomib—PSMD1—eye—melanoma	0.0031	0.0296	CbGeAlD
Bortezomib—PSMD1—retina—melanoma	0.00308	0.0293	CbGeAlD
Bortezomib—CTSG—mammalian vulva—melanoma	0.00306	0.0291	CbGeAlD
Bortezomib—PSMD2—eye—melanoma	0.00275	0.0262	CbGeAlD
Bortezomib—PSMD2—retina—melanoma	0.00272	0.0259	CbGeAlD
Bortezomib—PSMD1—mammalian vulva—melanoma	0.00246	0.0235	CbGeAlD
Bortezomib—PSMD2—skin of body—melanoma	0.00239	0.0228	CbGeAlD
Bortezomib—PSMD2—mammalian vulva—melanoma	0.00218	0.0208	CbGeAlD
Bortezomib—PSMB8—mammalian vulva—melanoma	0.00217	0.0206	CbGeAlD
Bortezomib—PSMB1—eye—melanoma	0.00211	0.0201	CbGeAlD
Bortezomib—PSMA1—head—melanoma	0.0021	0.02	CbGeAlD
Bortezomib—PSMB2—eye—melanoma	0.00206	0.0196	CbGeAlD
Bortezomib—PSMB2—retina—melanoma	0.00204	0.0194	CbGeAlD
Bortezomib—PSMB5—mammalian vulva—melanoma	0.00192	0.0182	CbGeAlD
Bortezomib—PSMB1—skin of body—melanoma	0.00184	0.0175	CbGeAlD
Bortezomib—PSMB2—skin of body—melanoma	0.00179	0.0171	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—melanoma	0.0017	0.0162	CbGeAlD
Bortezomib—PSMB1—mammalian vulva—melanoma	0.00167	0.0159	CbGeAlD
Bortezomib—PSMB2—mammalian vulva—melanoma	0.00163	0.0156	CbGeAlD
Bortezomib—PSMD2—head—melanoma	0.00156	0.0149	CbGeAlD
Bortezomib—CTSG—lymph node—melanoma	0.00153	0.0146	CbGeAlD
Bortezomib—PSMA1—lymph node—melanoma	0.00147	0.014	CbGeAlD
Bortezomib—SLC31A1—mammalian vulva—melanoma	0.00141	0.0135	CbGeAlD
Bortezomib—Lacosamide—SCN10A—melanoma	0.0014	0.383	CrCbGaD
Bortezomib—Nateglinide—SLC15A2—melanoma	0.00126	0.345	CrCbGaD
Bortezomib—PSMD1—lymph node—melanoma	0.00123	0.0117	CbGeAlD
Bortezomib—PSMB1—head—melanoma	0.0012	0.0114	CbGeAlD
Bortezomib—PSMB2—head—melanoma	0.00117	0.0111	CbGeAlD
Bortezomib—PSMD2—lymph node—melanoma	0.00109	0.0104	CbGeAlD
Bortezomib—PSMB8—lymph node—melanoma	0.00109	0.0103	CbGeAlD
Bortezomib—PTGS1—endothelium—melanoma	0.00108	0.0103	CbGeAlD
Bortezomib—SLC31A1—head—melanoma	0.00101	0.00964	CbGeAlD
Bortezomib—PTGS1—blood vessel—melanoma	0.001	0.00952	CbGeAlD
Bortezomib—PSMB5—lymph node—melanoma	0.00096	0.00914	CbGeAlD
Bortezomib—PSMB1—lymph node—melanoma	0.000839	0.00799	CbGeAlD
Bortezomib—PSMB2—lymph node—melanoma	0.000818	0.00779	CbGeAlD
Bortezomib—Nateglinide—PPARG—melanoma	0.000721	0.197	CrCbGaD
Bortezomib—SLC31A1—lymph node—melanoma	0.000709	0.00675	CbGeAlD
Bortezomib—CYP1A1—skin of body—melanoma	0.000527	0.00502	CbGeAlD
Bortezomib—CYP1A1—mammalian vulva—melanoma	0.00048	0.00457	CbGeAlD
Bortezomib—PTGS1—skin of body—melanoma	0.000463	0.00441	CbGeAlD
Bortezomib—PTGS1—mammalian vulva—melanoma	0.000422	0.00402	CbGeAlD
Bortezomib—CYP1A1—head—melanoma	0.000344	0.00327	CbGeAlD
Bortezomib—PTGS1—head—melanoma	0.000302	0.00288	CbGeAlD
Bortezomib—Nateglinide—ALB—melanoma	0.000271	0.0743	CrCbGaD
Bortezomib—CYP2D6—head—melanoma	0.000248	0.00236	CbGeAlD
Bortezomib—CYP1A1—lymph node—melanoma	0.000241	0.00229	CbGeAlD
Bortezomib—PTGS1—lymph node—melanoma	0.000211	0.00201	CbGeAlD
Bortezomib—Cough—Bleomycin—melanoma	0.000191	0.000778	CcSEcCtD
Bortezomib—Chills—Temozolomide—melanoma	0.000191	0.000775	CcSEcCtD
Bortezomib—Dehydration—Docetaxel—melanoma	0.00019	0.000773	CcSEcCtD
Bortezomib—Ill-defined disorder—Dactinomycin—melanoma	0.00019	0.000772	CcSEcCtD
Bortezomib—Anaemia—Dactinomycin—melanoma	0.000189	0.000769	CcSEcCtD
Bortezomib—Vomiting—Vemurafenib—melanoma	0.000188	0.000764	CcSEcCtD
Bortezomib—Dry skin—Docetaxel—melanoma	0.000187	0.000761	CcSEcCtD
Bortezomib—Chest pain—Bleomycin—melanoma	0.000187	0.000759	CcSEcCtD
Bortezomib—Myalgia—Bleomycin—melanoma	0.000187	0.000759	CcSEcCtD
Bortezomib—Orthostatic hypotension—Docetaxel—melanoma	0.000187	0.000759	CcSEcCtD
Bortezomib—Abdominal pain upper—Docetaxel—melanoma	0.000187	0.000759	CcSEcCtD
Bortezomib—Rash—Vemurafenib—melanoma	0.000186	0.000757	CcSEcCtD
Bortezomib—Mental disorder—Temozolomide—melanoma	0.000186	0.000757	CcSEcCtD
Bortezomib—Dermatitis—Vemurafenib—melanoma	0.000186	0.000757	CcSEcCtD
Bortezomib—Back pain—Carmustine—melanoma	0.000185	0.000753	CcSEcCtD
Bortezomib—Headache—Vemurafenib—melanoma	0.000185	0.000753	CcSEcCtD
Bortezomib—Malnutrition—Temozolomide—melanoma	0.000185	0.000752	CcSEcCtD
Bortezomib—Erythema—Temozolomide—melanoma	0.000185	0.000752	CcSEcCtD
Bortezomib—Breast disorder—Docetaxel—melanoma	0.000185	0.000751	CcSEcCtD
Bortezomib—Discomfort—Bleomycin—melanoma	0.000185	0.00075	CcSEcCtD
Bortezomib—Malaise—Dactinomycin—melanoma	0.000185	0.00075	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000184	0.000748	CcSEcCtD
Bortezomib—Cramp muscle—Docetaxel—melanoma	0.000184	0.000748	CcSEcCtD
Bortezomib—Leukopenia—Dactinomycin—melanoma	0.000183	0.000745	CcSEcCtD
Bortezomib—Nasopharyngitis—Docetaxel—melanoma	0.000183	0.000743	CcSEcCtD
Bortezomib—Dysgeusia—Temozolomide—melanoma	0.000181	0.000737	CcSEcCtD
Bortezomib—Confusional state—Bleomycin—melanoma	0.000181	0.000734	CcSEcCtD
Bortezomib—Vision blurred—Carmustine—melanoma	0.00018	0.000734	CcSEcCtD
Bortezomib—Tremor—Carmustine—melanoma	0.000179	0.000729	CcSEcCtD
Bortezomib—Anaphylactic shock—Bleomycin—melanoma	0.000179	0.000728	CcSEcCtD
Bortezomib—Oedema—Bleomycin—melanoma	0.000179	0.000728	CcSEcCtD
Bortezomib—Back pain—Temozolomide—melanoma	0.000179	0.000728	CcSEcCtD
Bortezomib—Infection—Bleomycin—melanoma	0.000178	0.000723	CcSEcCtD
Bortezomib—Anaemia—Carmustine—melanoma	0.000177	0.00072	CcSEcCtD
Bortezomib—Dysphagia—Docetaxel—melanoma	0.000177	0.000718	CcSEcCtD
Bortezomib—Agitation—Carmustine—melanoma	0.000176	0.000715	CcSEcCtD
Bortezomib—Nausea—Vemurafenib—melanoma	0.000176	0.000714	CcSEcCtD
Bortezomib—Thrombocytopenia—Bleomycin—melanoma	0.000175	0.000713	CcSEcCtD
Bortezomib—Vision blurred—Temozolomide—melanoma	0.000174	0.000709	CcSEcCtD
Bortezomib—Myalgia—Dactinomycin—melanoma	0.000174	0.000708	CcSEcCtD
Bortezomib—Bronchospasm—Docetaxel—melanoma	0.000174	0.000706	CcSEcCtD
Bortezomib—Tremor—Temozolomide—melanoma	0.000173	0.000705	CcSEcCtD
Bortezomib—Discomfort—Dactinomycin—melanoma	0.000172	0.0007	CcSEcCtD
Bortezomib—Angina pectoris—Docetaxel—melanoma	0.000172	0.000699	CcSEcCtD
Bortezomib—Ill-defined disorder—Temozolomide—melanoma	0.000172	0.000698	CcSEcCtD
Bortezomib—Leukopenia—Carmustine—melanoma	0.000171	0.000697	CcSEcCtD
Bortezomib—Anaemia—Temozolomide—melanoma	0.000171	0.000695	CcSEcCtD
Bortezomib—Anorexia—Bleomycin—melanoma	0.000171	0.000694	CcSEcCtD
Bortezomib—Agitation—Temozolomide—melanoma	0.00017	0.000691	CcSEcCtD
Bortezomib—Angioedema—Temozolomide—melanoma	0.000169	0.000687	CcSEcCtD
Bortezomib—Pancytopenia—Docetaxel—melanoma	0.000168	0.000682	CcSEcCtD
Bortezomib—Hypotension—Bleomycin—melanoma	0.000167	0.00068	CcSEcCtD
Bortezomib—Oedema—Dactinomycin—melanoma	0.000167	0.000679	CcSEcCtD
Bortezomib—Malaise—Temozolomide—melanoma	0.000167	0.000678	CcSEcCtD
Bortezomib—Vertigo—Temozolomide—melanoma	0.000166	0.000676	CcSEcCtD
Bortezomib—Convulsion—Carmustine—melanoma	0.000166	0.000674	CcSEcCtD
Bortezomib—Infection—Dactinomycin—melanoma	0.000166	0.000674	CcSEcCtD
Bortezomib—Leukopenia—Temozolomide—melanoma	0.000166	0.000673	CcSEcCtD
Bortezomib—Hypertension—Carmustine—melanoma	0.000165	0.000672	CcSEcCtD
Bortezomib—Neutropenia—Docetaxel—melanoma	0.000165	0.000671	CcSEcCtD
Bortezomib—Palpitations—Temozolomide—melanoma	0.000164	0.000665	CcSEcCtD
Bortezomib—Thrombocytopenia—Dactinomycin—melanoma	0.000163	0.000665	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000163	0.000663	CcSEcCtD
Bortezomib—Myalgia—Carmustine—melanoma	0.000163	0.000663	CcSEcCtD
Bortezomib—Chest pain—Carmustine—melanoma	0.000163	0.000663	CcSEcCtD
Bortezomib—Anxiety—Carmustine—melanoma	0.000162	0.00066	CcSEcCtD
Bortezomib—Cough—Temozolomide—melanoma	0.000161	0.000656	CcSEcCtD
Bortezomib—Paraesthesia—Bleomycin—melanoma	0.000161	0.000654	CcSEcCtD
Bortezomib—Weight increased—Docetaxel—melanoma	0.000161	0.000653	CcSEcCtD
Bortezomib—Convulsion—Temozolomide—melanoma	0.00016	0.000652	CcSEcCtD
Bortezomib—Weight decreased—Docetaxel—melanoma	0.00016	0.00065	CcSEcCtD
Bortezomib—Hypertension—Temozolomide—melanoma	0.00016	0.00065	CcSEcCtD
Bortezomib—Dyspnoea—Bleomycin—melanoma	0.00016	0.000649	CcSEcCtD
Bortezomib—Anorexia—Dactinomycin—melanoma	0.000159	0.000647	CcSEcCtD
Bortezomib—Pneumonia—Docetaxel—melanoma	0.000158	0.000644	CcSEcCtD
Bortezomib—Confusional state—Carmustine—melanoma	0.000158	0.000641	CcSEcCtD
Bortezomib—Arthralgia—Temozolomide—melanoma	0.000158	0.00064	CcSEcCtD
Bortezomib—Myalgia—Temozolomide—melanoma	0.000158	0.00064	CcSEcCtD
Bortezomib—Infestation NOS—Docetaxel—melanoma	0.000157	0.00064	CcSEcCtD
Bortezomib—Infestation—Docetaxel—melanoma	0.000157	0.00064	CcSEcCtD
Bortezomib—Anxiety—Temozolomide—melanoma	0.000157	0.000638	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000156	0.000636	CcSEcCtD
Bortezomib—Oedema—Carmustine—melanoma	0.000156	0.000635	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000156	0.000635	CcSEcCtD
Bortezomib—Discomfort—Temozolomide—melanoma	0.000156	0.000633	CcSEcCtD
Bortezomib—Decreased appetite—Bleomycin—melanoma	0.000156	0.000633	CcSEcCtD
Bortezomib—Infection—Carmustine—melanoma	0.000155	0.000631	CcSEcCtD
Bortezomib—Acute coronary syndrome—Docetaxel—melanoma	0.000155	0.000631	CcSEcCtD
Bortezomib—Renal failure—Docetaxel—melanoma	0.000155	0.000629	CcSEcCtD
Bortezomib—Myocardial infarction—Docetaxel—melanoma	0.000154	0.000628	CcSEcCtD
Bortezomib—Neuropathy peripheral—Docetaxel—melanoma	0.000154	0.000628	CcSEcCtD
Bortezomib—Stomatitis—Docetaxel—melanoma	0.000154	0.000624	CcSEcCtD
Bortezomib—Pain—Bleomycin—melanoma	0.000153	0.000622	CcSEcCtD
Bortezomib—Conjunctivitis—Docetaxel—melanoma	0.000153	0.000622	CcSEcCtD
Bortezomib—Thrombocytopenia—Carmustine—melanoma	0.000153	0.000622	CcSEcCtD
Bortezomib—Tachycardia—Carmustine—melanoma	0.000153	0.00062	CcSEcCtD
Bortezomib—Confusional state—Temozolomide—melanoma	0.000152	0.000619	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000152	0.000618	CcSEcCtD
Bortezomib—Oedema—Temozolomide—melanoma	0.000151	0.000614	CcSEcCtD
Bortezomib—Anaphylactic shock—Temozolomide—melanoma	0.000151	0.000614	CcSEcCtD
Bortezomib—Infection—Temozolomide—melanoma	0.00015	0.00061	CcSEcCtD
Bortezomib—Anorexia—Carmustine—melanoma	0.000149	0.000606	CcSEcCtD
Bortezomib—Hepatobiliary disease—Docetaxel—melanoma	0.000149	0.000605	CcSEcCtD
Bortezomib—Epistaxis—Docetaxel—melanoma	0.000149	0.000604	CcSEcCtD
Bortezomib—Nervous system disorder—Temozolomide—melanoma	0.000148	0.000602	CcSEcCtD
Bortezomib—Thrombocytopenia—Temozolomide—melanoma	0.000148	0.000601	CcSEcCtD
Bortezomib—Feeling abnormal—Bleomycin—melanoma	0.000148	0.0006	CcSEcCtD
Bortezomib—Skin disorder—Temozolomide—melanoma	0.000147	0.000596	CcSEcCtD
Bortezomib—Hypotension—Carmustine—melanoma	0.000146	0.000594	CcSEcCtD
Bortezomib—Hyperhidrosis—Temozolomide—melanoma	0.000146	0.000594	CcSEcCtD
Bortezomib—Decreased appetite—Dactinomycin—melanoma	0.000145	0.00059	CcSEcCtD
Bortezomib—Fatigue—Dactinomycin—melanoma	0.000144	0.000585	CcSEcCtD
Bortezomib—Anorexia—Temozolomide—melanoma	0.000144	0.000585	CcSEcCtD
Bortezomib—Pain—Dactinomycin—melanoma	0.000143	0.00058	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Carmustine—melanoma	0.000142	0.000579	CcSEcCtD
Bortezomib—Urticaria—Bleomycin—melanoma	0.000142	0.000578	CcSEcCtD
Bortezomib—Haemoglobin—Docetaxel—melanoma	0.000142	0.000578	CcSEcCtD
Bortezomib—Body temperature increased—Bleomycin—melanoma	0.000142	0.000575	CcSEcCtD
Bortezomib—Haemorrhage—Docetaxel—melanoma	0.000141	0.000575	CcSEcCtD
Bortezomib—Hepatitis—Docetaxel—melanoma	0.000141	0.000575	CcSEcCtD
Bortezomib—Insomnia—Carmustine—melanoma	0.000141	0.000575	CcSEcCtD
Bortezomib—Hypoaesthesia—Docetaxel—melanoma	0.000141	0.000572	CcSEcCtD
Bortezomib—Paraesthesia—Carmustine—melanoma	0.00014	0.000571	CcSEcCtD
Bortezomib—Urinary tract disorder—Docetaxel—melanoma	0.00014	0.000568	CcSEcCtD
Bortezomib—Dyspnoea—Carmustine—melanoma	0.000139	0.000566	CcSEcCtD
Bortezomib—Oedema peripheral—Docetaxel—melanoma	0.000139	0.000566	CcSEcCtD
Bortezomib—Connective tissue disorder—Docetaxel—melanoma	0.000139	0.000565	CcSEcCtD
Bortezomib—Urethral disorder—Docetaxel—melanoma	0.000139	0.000563	CcSEcCtD
Bortezomib—Feeling abnormal—Dactinomycin—melanoma	0.000138	0.000559	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000138	0.000559	CcSEcCtD
Bortezomib—Insomnia—Temozolomide—melanoma	0.000137	0.000555	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dactinomycin—melanoma	0.000137	0.000555	CcSEcCtD
Bortezomib—Visual impairment—Docetaxel—melanoma	0.000136	0.000554	CcSEcCtD
Bortezomib—Decreased appetite—Carmustine—melanoma	0.000136	0.000552	CcSEcCtD
Bortezomib—Paraesthesia—Temozolomide—melanoma	0.000136	0.000551	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Carmustine—melanoma	0.000135	0.000549	CcSEcCtD
Bortezomib—Dyspnoea—Temozolomide—melanoma	0.000135	0.000547	CcSEcCtD
Bortezomib—Erythema multiforme—Docetaxel—melanoma	0.000134	0.000543	CcSEcCtD
Bortezomib—Pain—Carmustine—melanoma	0.000134	0.000543	CcSEcCtD
Bortezomib—Constipation—Carmustine—melanoma	0.000134	0.000543	CcSEcCtD
Bortezomib—Dyspepsia—Temozolomide—melanoma	0.000133	0.00054	CcSEcCtD
Bortezomib—Eye disorder—Docetaxel—melanoma	0.000132	0.000537	CcSEcCtD
Bortezomib—Abdominal pain—Dactinomycin—melanoma	0.000132	0.000537	CcSEcCtD
Bortezomib—Body temperature increased—Dactinomycin—melanoma	0.000132	0.000537	CcSEcCtD
Bortezomib—Hypersensitivity—Bleomycin—melanoma	0.000132	0.000536	CcSEcCtD
Bortezomib—Decreased appetite—Temozolomide—melanoma	0.000131	0.000534	CcSEcCtD
Bortezomib—Cardiac disorder—Docetaxel—melanoma	0.000131	0.000533	CcSEcCtD
Bortezomib—Flushing—Docetaxel—melanoma	0.000131	0.000533	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Temozolomide—melanoma	0.00013	0.00053	CcSEcCtD
Bortezomib—Fatigue—Temozolomide—melanoma	0.00013	0.000529	CcSEcCtD
Bortezomib—Pain—Temozolomide—melanoma	0.000129	0.000525	CcSEcCtD
Bortezomib—Constipation—Temozolomide—melanoma	0.000129	0.000525	CcSEcCtD
Bortezomib—Feeling abnormal—Carmustine—melanoma	0.000129	0.000524	CcSEcCtD
Bortezomib—Asthenia—Bleomycin—melanoma	0.000128	0.000522	CcSEcCtD
Bortezomib—Angiopathy—Docetaxel—melanoma	0.000128	0.000521	CcSEcCtD
Bortezomib—Gastrointestinal pain—Carmustine—melanoma	0.000128	0.00052	CcSEcCtD
Bortezomib—Immune system disorder—Docetaxel—melanoma	0.000128	0.000519	CcSEcCtD
Bortezomib—Mediastinal disorder—Docetaxel—melanoma	0.000127	0.000518	CcSEcCtD
Bortezomib—Chills—Docetaxel—melanoma	0.000127	0.000516	CcSEcCtD
Bortezomib—Pruritus—Bleomycin—melanoma	0.000127	0.000515	CcSEcCtD
Bortezomib—Arrhythmia—Docetaxel—melanoma	0.000126	0.000513	CcSEcCtD
Bortezomib—Feeling abnormal—Temozolomide—melanoma	0.000124	0.000506	CcSEcCtD
Bortezomib—Mental disorder—Docetaxel—melanoma	0.000124	0.000503	CcSEcCtD
Bortezomib—Body temperature increased—Carmustine—melanoma	0.000124	0.000502	CcSEcCtD
Bortezomib—Abdominal pain—Carmustine—melanoma	0.000124	0.000502	CcSEcCtD
Bortezomib—Gastrointestinal pain—Temozolomide—melanoma	0.000124	0.000502	CcSEcCtD
Bortezomib—Malnutrition—Docetaxel—melanoma	0.000123	0.0005	CcSEcCtD
Bortezomib—Erythema—Docetaxel—melanoma	0.000123	0.0005	CcSEcCtD
Bortezomib—Hypersensitivity—Dactinomycin—melanoma	0.000123	0.0005	CcSEcCtD
Bortezomib—Dysgeusia—Docetaxel—melanoma	0.000121	0.00049	CcSEcCtD
Bortezomib—Urticaria—Temozolomide—melanoma	0.00012	0.000488	CcSEcCtD
Bortezomib—Asthenia—Dactinomycin—melanoma	0.00012	0.000487	CcSEcCtD
Bortezomib—Body temperature increased—Temozolomide—melanoma	0.000119	0.000485	CcSEcCtD
Bortezomib—Abdominal pain—Temozolomide—melanoma	0.000119	0.000485	CcSEcCtD
Bortezomib—Back pain—Docetaxel—melanoma	0.000119	0.000484	CcSEcCtD
Bortezomib—Muscle spasms—Docetaxel—melanoma	0.000118	0.000481	CcSEcCtD
Bortezomib—Hypersensitivity—Carmustine—melanoma	0.000115	0.000468	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—melanoma	0.000114	0.000464	CcSEcCtD
Bortezomib—Vomiting—Bleomycin—melanoma	0.000114	0.000463	CcSEcCtD
Bortezomib—Anaemia—Docetaxel—melanoma	0.000114	0.000462	CcSEcCtD
Bortezomib—Rash—Bleomycin—melanoma	0.000113	0.000459	CcSEcCtD
Bortezomib—Dermatitis—Bleomycin—melanoma	0.000113	0.000459	CcSEcCtD
Bortezomib—Asthenia—Carmustine—melanoma	0.000112	0.000456	CcSEcCtD
Bortezomib—Hypersensitivity—Temozolomide—melanoma	0.000111	0.000452	CcSEcCtD
Bortezomib—Syncope—Docetaxel—melanoma	0.00011	0.000449	CcSEcCtD
Bortezomib—Leukopenia—Docetaxel—melanoma	0.00011	0.000448	CcSEcCtD
Bortezomib—Palpitations—Docetaxel—melanoma	0.000109	0.000442	CcSEcCtD
Bortezomib—Asthenia—Temozolomide—melanoma	0.000108	0.000441	CcSEcCtD
Bortezomib—Loss of consciousness—Docetaxel—melanoma	0.000108	0.00044	CcSEcCtD
Bortezomib—Cough—Docetaxel—melanoma	0.000107	0.000437	CcSEcCtD
Bortezomib—Diarrhoea—Carmustine—melanoma	0.000107	0.000435	CcSEcCtD
Bortezomib—Pruritus—Temozolomide—melanoma	0.000107	0.000434	CcSEcCtD
Bortezomib—Convulsion—Docetaxel—melanoma	0.000107	0.000433	CcSEcCtD
Bortezomib—Nausea—Bleomycin—melanoma	0.000106	0.000432	CcSEcCtD
Bortezomib—Hypertension—Docetaxel—melanoma	0.000106	0.000432	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—melanoma	0.000106	0.000432	CcSEcCtD
Bortezomib—Rash—Dactinomycin—melanoma	0.000105	0.000428	CcSEcCtD
Bortezomib—Arthralgia—Docetaxel—melanoma	0.000105	0.000426	CcSEcCtD
Bortezomib—Myalgia—Docetaxel—melanoma	0.000105	0.000426	CcSEcCtD
Bortezomib—Chest pain—Docetaxel—melanoma	0.000105	0.000426	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000104	0.000423	CcSEcCtD
Bortezomib—Dizziness—Carmustine—melanoma	0.000103	0.00042	CcSEcCtD
Bortezomib—Diarrhoea—Temozolomide—melanoma	0.000103	0.00042	CcSEcCtD
Bortezomib—Confusional state—Docetaxel—melanoma	0.000101	0.000412	CcSEcCtD
Bortezomib—Anaphylactic shock—Docetaxel—melanoma	0.0001	0.000408	CcSEcCtD
Bortezomib—Oedema—Docetaxel—melanoma	0.0001	0.000408	CcSEcCtD
Bortezomib—Dizziness—Temozolomide—melanoma	9.99e-05	0.000406	CcSEcCtD
Bortezomib—Infection—Docetaxel—melanoma	9.98e-05	0.000406	CcSEcCtD
Bortezomib—Vomiting—Carmustine—melanoma	9.94e-05	0.000404	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—melanoma	9.92e-05	0.000403	CcSEcCtD
Bortezomib—Shock—Docetaxel—melanoma	9.88e-05	0.000402	CcSEcCtD
Bortezomib—Rash—Carmustine—melanoma	9.85e-05	0.000401	CcSEcCtD
Bortezomib—Nervous system disorder—Docetaxel—melanoma	9.85e-05	0.0004	CcSEcCtD
Bortezomib—Dermatitis—Carmustine—melanoma	9.85e-05	0.0004	CcSEcCtD
Bortezomib—Thrombocytopenia—Docetaxel—melanoma	9.83e-05	0.0004	CcSEcCtD
Bortezomib—Tachycardia—Docetaxel—melanoma	9.8e-05	0.000398	CcSEcCtD
Bortezomib—Headache—Carmustine—melanoma	9.79e-05	0.000398	CcSEcCtD
Bortezomib—Skin disorder—Docetaxel—melanoma	9.76e-05	0.000397	CcSEcCtD
Bortezomib—Vomiting—Temozolomide—melanoma	9.6e-05	0.00039	CcSEcCtD
Bortezomib—Anorexia—Docetaxel—melanoma	9.57e-05	0.000389	CcSEcCtD
Bortezomib—Rash—Temozolomide—melanoma	9.52e-05	0.000387	CcSEcCtD
Bortezomib—Dermatitis—Temozolomide—melanoma	9.51e-05	0.000387	CcSEcCtD
Bortezomib—Headache—Temozolomide—melanoma	9.46e-05	0.000385	CcSEcCtD
Bortezomib—Hypotension—Docetaxel—melanoma	9.39e-05	0.000382	CcSEcCtD
Bortezomib—Nausea—Carmustine—melanoma	9.28e-05	0.000377	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Docetaxel—melanoma	9.15e-05	0.000372	CcSEcCtD
Bortezomib—Insomnia—Docetaxel—melanoma	9.08e-05	0.000369	CcSEcCtD
Bortezomib—Paraesthesia—Docetaxel—melanoma	9.02e-05	0.000367	CcSEcCtD
Bortezomib—Nausea—Temozolomide—melanoma	8.97e-05	0.000365	CcSEcCtD
Bortezomib—Dyspnoea—Docetaxel—melanoma	8.95e-05	0.000364	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—melanoma	8.84e-05	0.000359	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—melanoma	8.73e-05	0.000355	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—melanoma	8.67e-05	0.000353	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—melanoma	8.66e-05	0.000352	CcSEcCtD
Bortezomib—Pain—Docetaxel—melanoma	8.59e-05	0.000349	CcSEcCtD
Bortezomib—Constipation—Docetaxel—melanoma	8.59e-05	0.000349	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—melanoma	8.28e-05	0.000336	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—melanoma	8.21e-05	0.000334	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—melanoma	7.94e-05	0.000323	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—melanoma	7.94e-05	0.000323	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—melanoma	7.4e-05	0.000301	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—melanoma	7.21e-05	0.000293	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—melanoma	7.11e-05	0.000289	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—melanoma	6.87e-05	0.000279	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—melanoma	6.64e-05	0.00027	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—melanoma	6.39e-05	0.00026	CcSEcCtD
Bortezomib—Rash—Docetaxel—melanoma	6.33e-05	0.000257	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—melanoma	6.33e-05	0.000257	CcSEcCtD
Bortezomib—Headache—Docetaxel—melanoma	6.29e-05	0.000256	CcSEcCtD
Bortezomib—Nausea—Docetaxel—melanoma	5.97e-05	0.000243	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—melanoma	4.18e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—melanoma	4.17e-06	1.44e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKB1—melanoma	4.15e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.14e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.09e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—melanoma	4.08e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—melanoma	4.08e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—melanoma	4.08e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD44—melanoma	4.04e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNAQ—melanoma	4.04e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—melanoma	4.03e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	4.03e-06	1.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNA11—melanoma	4e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CG—melanoma	3.99e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNA11—melanoma	3.97e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.96e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—melanoma	3.94e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—melanoma	3.94e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—melanoma	3.94e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—melanoma	3.93e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.92e-06	1.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—melanoma	3.92e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—FASN—melanoma	3.91e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—melanoma	3.9e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—melanoma	3.9e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.89e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—melanoma	3.88e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—FASN—melanoma	3.88e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1B1—melanoma	3.88e-06	1.34e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—melanoma	3.85e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC5A5—melanoma	3.85e-06	1.34e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—melanoma	3.84e-06	1.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.83e-06	1.33e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—melanoma	3.83e-06	1.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—melanoma	3.82e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—melanoma	3.82e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—melanoma	3.82e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC5A5—melanoma	3.82e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—melanoma	3.81e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—melanoma	3.81e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—melanoma	3.79e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—melanoma	3.78e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—melanoma	3.78e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—melanoma	3.78e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—melanoma	3.77e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—melanoma	3.76e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—melanoma	3.75e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—melanoma	3.75e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—melanoma	3.75e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—melanoma	3.73e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNAQ—melanoma	3.72e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD44—melanoma	3.72e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—melanoma	3.72e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—melanoma	3.72e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—melanoma	3.71e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—melanoma	3.69e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNAQ—melanoma	3.69e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD44—melanoma	3.69e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLA2G6—melanoma	3.65e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—melanoma	3.64e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—melanoma	3.62e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK3—melanoma	3.61e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK3—melanoma	3.61e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK3—melanoma	3.61e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.61e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—melanoma	3.61e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PRKCA—melanoma	3.59e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP17A1—melanoma	3.59e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.58e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—melanoma	3.58e-06	1.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—melanoma	3.57e-06	1.24e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—melanoma	3.57e-06	1.24e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—melanoma	3.57e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1B1—melanoma	3.57e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ERCC2—melanoma	3.56e-06	1.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK3—melanoma	3.56e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.54e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1B1—melanoma	3.53e-06	1.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—melanoma	3.52e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—melanoma	3.51e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—melanoma	3.51e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—melanoma	3.51e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—melanoma	3.51e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	3.49e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—melanoma	3.48e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—melanoma	3.48e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—melanoma	3.48e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—melanoma	3.48e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—melanoma	3.47e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—melanoma	3.46e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—melanoma	3.46e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—melanoma	3.45e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—melanoma	3.44e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—melanoma	3.43e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.42e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNA11—melanoma	3.39e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—melanoma	3.39e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—melanoma	3.39e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—FASN—melanoma	3.32e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PRKCA—melanoma	3.29e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—VCAN—melanoma	3.28e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—melanoma	3.26e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC5A5—melanoma	3.26e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—melanoma	3.25e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—melanoma	3.25e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—melanoma	3.25e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—melanoma	3.21e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—melanoma	3.2e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—melanoma	3.2e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—melanoma	3.19e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—melanoma	3.18e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNAQ—melanoma	3.15e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD44—melanoma	3.15e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.12e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.08e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—melanoma	3.06e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.06e-06	1.06e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—melanoma	3.03e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1B1—melanoma	3.02e-06	1.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—melanoma	2.98e-06	1.03e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—melanoma	2.98e-06	1.03e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—melanoma	2.98e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.95e-06	1.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—melanoma	2.94e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PRKCA—melanoma	2.94e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—melanoma	2.94e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—melanoma	2.91e-06	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—melanoma	2.91e-06	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—melanoma	2.91e-06	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—melanoma	2.91e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—melanoma	2.91e-06	1.01e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—melanoma	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—melanoma	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—melanoma	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—melanoma	2.87e-06	9.96e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—melanoma	2.84e-06	9.86e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—melanoma	2.81e-06	9.75e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP17A1—melanoma	2.77e-06	9.6e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—melanoma	2.76e-06	9.57e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—melanoma	2.76e-06	9.57e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—melanoma	2.76e-06	9.57e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—melanoma	2.72e-06	9.43e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—melanoma	2.71e-06	9.41e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.7e-06	9.38e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PRKCA—melanoma	2.7e-06	9.37e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—melanoma	2.68e-06	9.29e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PRKCA—melanoma	2.68e-06	9.29e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.67e-06	9.24e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—melanoma	2.66e-06	9.21e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—melanoma	2.64e-06	9.16e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—melanoma	2.64e-06	9.16e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—melanoma	2.64e-06	9.16e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—melanoma	2.64e-06	9.16e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNA11—melanoma	2.62e-06	9.07e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—melanoma	2.6e-06	9.03e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—melanoma	2.58e-06	8.94e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FASN—melanoma	2.56e-06	8.87e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A5—melanoma	2.52e-06	8.73e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—melanoma	2.49e-06	8.63e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—melanoma	2.49e-06	8.62e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—melanoma	2.47e-06	8.57e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—melanoma	2.44e-06	8.46e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—melanoma	2.44e-06	8.45e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—melanoma	2.44e-06	8.45e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—melanoma	2.44e-06	8.45e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNAQ—melanoma	2.43e-06	8.43e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD44—melanoma	2.43e-06	8.43e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.41e-06	8.37e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—melanoma	2.4e-06	8.33e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1B1—melanoma	2.33e-06	8.08e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—melanoma	2.3e-06	7.98e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PRKCA—melanoma	2.29e-06	7.94e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—melanoma	2.27e-06	7.87e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—melanoma	2.27e-06	7.86e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—melanoma	2.24e-06	7.76e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—melanoma	2.22e-06	7.7e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.2e-06	7.63e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—melanoma	2.15e-06	7.47e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—melanoma	2.13e-06	7.4e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—melanoma	2.12e-06	7.34e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—melanoma	2.1e-06	7.28e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—melanoma	2.04e-06	7.08e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—melanoma	2.02e-06	7.02e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—melanoma	2.02e-06	7.01e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—melanoma	2e-06	6.92e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—melanoma	1.98e-06	6.85e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—melanoma	1.96e-06	6.79e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—melanoma	1.92e-06	6.66e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.88e-06	6.52e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—melanoma	1.86e-06	6.46e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—melanoma	1.86e-06	6.46e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—melanoma	1.86e-06	6.45e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—melanoma	1.84e-06	6.4e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—melanoma	1.84e-06	6.37e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—melanoma	1.82e-06	6.31e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—melanoma	1.79e-06	6.22e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PRKCA—melanoma	1.77e-06	6.13e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—melanoma	1.76e-06	6.11e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—melanoma	1.75e-06	6.08e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—melanoma	1.75e-06	6.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—melanoma	1.73e-06	6e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—melanoma	1.71e-06	5.92e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—melanoma	1.62e-06	5.62e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—melanoma	1.61e-06	5.57e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—melanoma	1.61e-06	5.57e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—melanoma	1.59e-06	5.52e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—melanoma	1.58e-06	5.47e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—melanoma	1.56e-06	5.4e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—melanoma	1.52e-06	5.28e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—melanoma	1.52e-06	5.28e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—melanoma	1.4e-06	4.86e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—melanoma	1.39e-06	4.82e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—melanoma	1.38e-06	4.8e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—melanoma	1.37e-06	4.76e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—melanoma	1.36e-06	4.72e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—melanoma	1.34e-06	4.63e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—melanoma	1.31e-06	4.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—melanoma	1.22e-06	4.22e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—melanoma	1.2e-06	4.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—melanoma	1.2e-06	4.16e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—melanoma	1.19e-06	4.12e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—melanoma	1.07e-06	3.73e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—melanoma	1.07e-06	3.72e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—melanoma	1.06e-06	3.68e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—melanoma	1.05e-06	3.64e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—melanoma	9.89e-07	3.43e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—melanoma	9.84e-07	3.41e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—melanoma	9.8e-07	3.4e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—melanoma	9.16e-07	3.18e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—melanoma	8.78e-07	3.04e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—melanoma	8.37e-07	2.9e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—melanoma	8.08e-07	2.8e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—melanoma	8.01e-07	2.78e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—melanoma	6.84e-07	2.37e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—melanoma	6.46e-07	2.24e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—melanoma	5.28e-07	1.83e-06	CbGpPWpGaD
